West Haven antivirus-drug developer NanoViricides Inc. has named a Baylor ophthalmology professor to its board of directors.
Milton Boniuk, who will join the company’s board immediately, is a veteran in ocular surgeries, practices, and research that has been advantageous to NanoViricides, including his work with ocular infections like the EKC virus, which causes cornea inflammation.
Boniuk, who plays a major role in Baylor’s resident and fellow medical doctor education programs, is also widely recognized as an expert in orbital and intra-ocular tumors.
“In addition to strengthening our corporate governance, [Dr. Boniuk] will be of great value in progressing our drug development programs into the clinic,” said Anil R. Diwan, the president of NanoViricides
NanoViricides is pursuing U.S. Food & Drug Administration review and approval of its broad-spectrum FluCide antiviral, seen as a potential blockbuster in treating most, if not all, influenza A viruses.
The company is also developing treatments for some of the world’s most prevalent and debilitating ailments traced to viruses, including bird and swine flu, herpes, HIV, ebola and dengue fever.
